Global Disease-Modifying Antirheumatic Drug Sales Market Report 2021
1 Disease-Modifying Antirheumatic Drug Market Overview
- 1.1 Disease-Modifying Antirheumatic Drug Product Scope
- 1.2 Disease-Modifying Antirheumatic Drug Segment by Type
- 1.2.1 Global Disease-Modifying Antirheumatic Drug Sales by Type (2016 & 2021 & 2027)
- 1.2.2 Non-Steroidal Anti-Inflammatory Drugs
- 1.2.3 Steroidal Anti-Inflammatory Drugs
- 1.2.4 Slow Acting Drug
- 1.2.5 Immunological Preparation
- 1.3 Disease-Modifying Antirheumatic Drug Segment by Application
- 1.3.1 Global Disease-Modifying Antirheumatic Drug Sales Comparison by Application (2016 & 2021 & 2027)
- 1.3.2 Pharmaceutical Industry
- 1.3.3 Hospital and Clinic
- 1.3.4 Other
- 1.4 Disease-Modifying Antirheumatic Drug Market Estimates and Forecasts (2016-2027)
- 1.4.1 Global Disease-Modifying Antirheumatic Drug Market Size in Value Growth Rate (2016-2027)
- 1.4.2 Global Disease-Modifying Antirheumatic Drug Market Size in Volume Growth Rate (2016-2027)
- 1.4.3 Global Disease-Modifying Antirheumatic Drug Price Trends (2016-2027)
2 Disease-Modifying Antirheumatic Drug Estimates and Forecasts by Region
- 2.1 Global Disease-Modifying Antirheumatic Drug Market Size by Region: 2016 VS 2021 VS 2027
- 2.2 Global Disease-Modifying Antirheumatic Drug Retrospective Market Scenario by Region (2016-2021)
- 2.2.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Region (2016-2021)
- 2.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Region (2016-2021)
- 2.3 Global Disease-Modifying Antirheumatic Drug Market Estimates and Forecasts by Region (2022-2027)
- 2.3.1 Global Disease-Modifying Antirheumatic Drug Sales Estimates and Forecasts by Region (2022-2027)
- 2.3.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Region (2022-2027)
- 2.4 Geographic Market Analysis: Market Facts & Figures
- 2.4.1 North America Disease-Modifying Antirheumatic Drug Estimates and Projections (2016-2027)
- 2.4.2 Europe Disease-Modifying Antirheumatic Drug Estimates and Projections (2016-2027)
- 2.4.3 China Disease-Modifying Antirheumatic Drug Estimates and Projections (2016-2027)
- 2.4.4 Japan Disease-Modifying Antirheumatic Drug Estimates and Projections (2016-2027)
- 2.4.5 Southeast Asia Disease-Modifying Antirheumatic Drug Estimates and Projections (2016-2027)
- 2.4.6 India Disease-Modifying Antirheumatic Drug Estimates and Projections (2016-2027)
3 Global Disease-Modifying Antirheumatic Drug Competition Landscape by Players
- 3.1 Global Top Disease-Modifying Antirheumatic Drug Players by Sales (2016-2021)
- 3.2 Global Top Disease-Modifying Antirheumatic Drug Players by Revenue (2016-2021)
- 3.3 Global Disease-Modifying Antirheumatic Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Disease-Modifying Antirheumatic Drug as of 2020)
- 3.4 Global Disease-Modifying Antirheumatic Drug Average Price by Company (2016-2021)
- 3.5 Manufacturers Disease-Modifying Antirheumatic Drug Manufacturing Sites, Area Served, Product Type
- 3.6 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Global Disease-Modifying Antirheumatic Drug Market Size by Type
- 4.1 Global Disease-Modifying Antirheumatic Drug Historic Market Review by Type (2016-2021)
- 4.1.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Type (2016-2021)
- 4.1.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Type (2016-2021)
- 4.1.3 Global Disease-Modifying Antirheumatic Drug Price by Type (2016-2021)
- 4.2 Global Disease-Modifying Antirheumatic Drug Market Estimates and Forecasts by Type (2022-2027)
- 4.2.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Type (2022-2027)
- 4.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Type (2022-2027)
- 4.2.3 Global Disease-Modifying Antirheumatic Drug Price Forecast by Type (2022-2027)
5 Global Disease-Modifying Antirheumatic Drug Market Size by Application
- 5.1 Global Disease-Modifying Antirheumatic Drug Historic Market Review by Application (2016-2021)
- 5.1.1 Global Disease-Modifying Antirheumatic Drug Sales Market Share by Application (2016-2021)
- 5.1.2 Global Disease-Modifying Antirheumatic Drug Revenue Market Share by Application (2016-2021)
- 5.1.3 Global Disease-Modifying Antirheumatic Drug Price by Application (2016-2021)
- 5.2 Global Disease-Modifying Antirheumatic Drug Market Estimates and Forecasts by Application (2022-2027)
- 5.2.1 Global Disease-Modifying Antirheumatic Drug Sales Forecast by Application (2022-2027)
- 5.2.2 Global Disease-Modifying Antirheumatic Drug Revenue Forecast by Application (2022-2027)
- 5.2.3 Global Disease-Modifying Antirheumatic Drug Price Forecast by Application (2022-2027)
6 North America Disease-Modifying Antirheumatic Drug Market Facts & Figures
- 6.1 North America Disease-Modifying Antirheumatic Drug Sales by Company
- 6.1.1 North America Disease-Modifying Antirheumatic Drug Sales by Company (2016-2021)
- 6.1.2 North America Disease-Modifying Antirheumatic Drug Revenue by Company (2016-2021)
- 6.2 North America Disease-Modifying Antirheumatic Drug Sales Breakdown by Type
- 6.2.1 North America Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2016-2021)
- 6.2.2 North America Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2022-2027)
- 6.3 North America Disease-Modifying Antirheumatic Drug Sales Breakdown by Application
- 6.3.1 North America Disease-Modifying Antirheumatic Drug Sales Breakdown by Application (2016-2021)
- 6.3.2 North America Disease-Modifying Antirheumatic Drug Sales Breakdown by Application (2022-2027)
7 Europe Disease-Modifying Antirheumatic Drug Market Facts & Figures
- 7.1 Europe Disease-Modifying Antirheumatic Drug Sales by Company
- 7.1.1 Europe Disease-Modifying Antirheumatic Drug Sales by Company (2016-2021)
- 7.1.2 Europe Disease-Modifying Antirheumatic Drug Revenue by Company (2016-2021)
- 7.2 Europe Disease-Modifying Antirheumatic Drug Sales Breakdown by Type
- 7.2.1 Europe Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2016-2021)
- 7.2.2 Europe Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2022-2027)
- 7.3 Europe Disease-Modifying Antirheumatic Drug Sales Breakdown by Application
- 7.3.1 Europe 130 Sales Breakdown by Application (2016-2021)
- 7.3.2 Europe 130 Sales Breakdown by Application (2022-2027)
8 China Disease-Modifying Antirheumatic Drug Market Facts & Figures
- 8.1 China Disease-Modifying Antirheumatic Drug Sales by Company
- 8.1.1 China Disease-Modifying Antirheumatic Drug Sales by Company (2016-2021)
- 8.1.2 China Disease-Modifying Antirheumatic Drug Revenue by Company (2016-2021)
- 8.2 China Disease-Modifying Antirheumatic Drug Sales Breakdown by Type
- 8.2.1 China Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2016-2021)
- 8.2.2 China Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2022-2027)
- 8.3 China Disease-Modifying Antirheumatic Drug Sales Breakdown by Application
- 8.3.1 China 245 Sales Breakdown by Application (2016-2021)
- 8.3.2 China 245 Sales Breakdown by Application (2022-2027)
9 Japan Disease-Modifying Antirheumatic Drug Market Facts & Figures
- 9.1 Japan Disease-Modifying Antirheumatic Drug Sales by Company
- 9.1.1 Japan Disease-Modifying Antirheumatic Drug Sales by Company (2016-2021)
- 9.1.2 Japan Disease-Modifying Antirheumatic Drug Revenue by Company (2016-2021)
- 9.2 Japan Disease-Modifying Antirheumatic Drug Sales Breakdown by Type
- 9.2.1 Japan Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2016-2021)
- 9.2.2 Japan Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2022-2027)
- 9.3 Japan Disease-Modifying Antirheumatic Drug Sales Breakdown by Application
- 9.3.1 Japan Feb. Sales Breakdown by Application (2016-2021)
- 9.3.2 Japan Feb. Sales Breakdown by Application (2022-2027)
10 Southeast Asia Disease-Modifying Antirheumatic Drug Market Facts & Figures
- 10.1 Southeast Asia Disease-Modifying Antirheumatic Drug Sales by Company
- 10.1.1 Southeast Asia Disease-Modifying Antirheumatic Drug Sales by Company (2016-2021)
- 10.1.2 Southeast Asia Disease-Modifying Antirheumatic Drug Revenue by Company (2016-2021)
- 10.2 Southeast Asia Disease-Modifying Antirheumatic Drug Sales Breakdown by Type
- 10.2.1 Southeast Asia Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2016-2021)
- 10.2.2 Southeast Asia Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2022-2027)
- 10.3 Southeast Asia Disease-Modifying Antirheumatic Drug Sales Breakdown by Application
- 10.3.1 Southeast Asia MT Sales Breakdown by Application (2016-2021)
- 10.3.2 Southeast Asia MT Sales Breakdown by Application (2022-2027)
11 India Disease-Modifying Antirheumatic Drug Market Facts & Figures
- 11.1 India Disease-Modifying Antirheumatic Drug Sales by Company
- 11.1.1 India Disease-Modifying Antirheumatic Drug Sales by Company (2016-2021)
- 11.1.2 India Disease-Modifying Antirheumatic Drug Revenue by Company (2016-2021)
- 11.2 India Disease-Modifying Antirheumatic Drug Sales Breakdown by Type
- 11.2.1 India Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2016-2021)
- 11.2.2 India Disease-Modifying Antirheumatic Drug Sales Breakdown by Type (2022-2027)
- 11.3 India Disease-Modifying Antirheumatic Drug Sales Breakdown by Application
- 11.3.1 India Disease-Modifying Antirheumatic Drug Sales Breakdown by Application (2016-2021)
- 11.3.2 India Disease-Modifying Antirheumatic Drug Sales Breakdown by Application (2022-2027)
12 Company Profiles and Key Figures in Disease-Modifying Antirheumatic Drug Business
- 12.1 AbbVie
- 12.1.1 AbbVie Corporation Information
- 12.1.2 AbbVie Business Overview
- 12.1.3 AbbVie Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.1.4 AbbVie Disease-Modifying Antirheumatic Drug Products Offered
- 12.1.5 AbbVie Recent Development
- 12.2 Amgen
- 12.2.1 Amgen Corporation Information
- 12.2.2 Amgen Business Overview
- 12.2.3 Amgen Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.2.4 Amgen Disease-Modifying Antirheumatic Drug Products Offered
- 12.2.5 Amgen Recent Development
- 12.3 Pfizer
- 12.3.1 Pfizer Corporation Information
- 12.3.2 Pfizer Business Overview
- 12.3.3 Pfizer Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.3.4 Pfizer Disease-Modifying Antirheumatic Drug Products Offered
- 12.3.5 Pfizer Recent Development
- 12.4 Roche Holding AG
- 12.4.1 Roche Holding AG Corporation Information
- 12.4.2 Roche Holding AG Business Overview
- 12.4.3 Roche Holding AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.4.4 Roche Holding AG Disease-Modifying Antirheumatic Drug Products Offered
- 12.4.5 Roche Holding AG Recent Development
- 12.5 Novartis International AG
- 12.5.1 Novartis International AG Corporation Information
- 12.5.2 Novartis International AG Business Overview
- 12.5.3 Novartis International AG Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.5.4 Novartis International AG Disease-Modifying Antirheumatic Drug Products Offered
- 12.5.5 Novartis International AG Recent Development
- 12.6 Johnson & Johnson
- 12.6.1 Johnson & Johnson Corporation Information
- 12.6.2 Johnson & Johnson Business Overview
- 12.6.3 Johnson & Johnson Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.6.4 Johnson & Johnson Disease-Modifying Antirheumatic Drug Products Offered
- 12.6.5 Johnson & Johnson Recent Development
- 12.7 Bristol-Myers Squibb
- 12.7.1 Bristol-Myers Squibb Corporation Information
- 12.7.2 Bristol-Myers Squibb Business Overview
- 12.7.3 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.7.4 Bristol-Myers Squibb Disease-Modifying Antirheumatic Drug Products Offered
- 12.7.5 Bristol-Myers Squibb Recent Development
- 12.8 Merck
- 12.8.1 Merck Corporation Information
- 12.8.2 Merck Business Overview
- 12.8.3 Merck Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.8.4 Merck Disease-Modifying Antirheumatic Drug Products Offered
- 12.8.5 Merck Recent Development
- 12.9 UCB S.A.
- 12.9.1 UCB S.A. Corporation Information
- 12.9.2 UCB S.A. Business Overview
- 12.9.3 UCB S.A. Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.9.4 UCB S.A. Disease-Modifying Antirheumatic Drug Products Offered
- 12.9.5 UCB S.A. Recent Development
- 12.10 Eli Lilly and Company
- 12.10.1 Eli Lilly and Company Corporation Information
- 12.10.2 Eli Lilly and Company Business Overview
- 12.10.3 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Sales, Revenue and Gross Margin (2016-2021)
- 12.10.4 Eli Lilly and Company Disease-Modifying Antirheumatic Drug Products Offered
- 12.10.5 Eli Lilly and Company Recent Development
13 Disease-Modifying Antirheumatic Drug Manufacturing Cost Analysis
- 13.1 Disease-Modifying Antirheumatic Drug Key Raw Materials Analysis
- 13.1.1 Key Raw Materials
- 13.1.2 Key Raw Materials Price Trend
- 13.1.3 Key Suppliers of Raw Materials
- 13.2 Proportion of Manufacturing Cost Structure
- 13.3 Manufacturing Process Analysis of Disease-Modifying Antirheumatic Drug
- 13.4 Disease-Modifying Antirheumatic Drug Industrial Chain Analysis
14 Marketing Channel, Distributors and Customers
- 14.1 Marketing Channel
- 14.2 Disease-Modifying Antirheumatic Drug Distributors List
- 14.3 Disease-Modifying Antirheumatic Drug Customers
15 Market Dynamics
- 15.1 Disease-Modifying Antirheumatic Drug Market Trends
- 15.2 Disease-Modifying Antirheumatic Drug Drivers
- 15.3 Disease-Modifying Antirheumatic Drug Market Challenges
- 15.4 Disease-Modifying Antirheumatic Drug Market Restraints
16 Research Findings and Conclusion
17 Appendix
- 17.1 Research Methodology
- 17.1.1 Methodology/Research Approach
- 17.1.2 Data Source
- 17.2 Author List
The global Disease-Modifying Antirheumatic Drug market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Disease-Modifying Antirheumatic Drug market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region (country), by Type and by Application for the period 2016-2027.
Segment by Type
Non-Steroidal Anti-Inflammatory Drugs
Steroidal Anti-Inflammatory Drugs
Slow Acting Drug
Immunological Preparation
Segment by Application
Pharmaceutical Industry
Hospital and Clinic
Other
The Disease-Modifying Antirheumatic Drug market is analysed and market size information is provided by regions (countries). Segment by Application, the Disease-Modifying Antirheumatic Drug market is segmented into North America, Europe, China, Japan, Southeast Asia, India and Other Regions.
By Company
AbbVie
Amgen
Pfizer
Roche Holding AG
Novartis International AG
Johnson & Johnson
Bristol-Myers Squibb
Merck
UCB S.A.
Eli Lilly and Company